Associate editor: P.C. Molenaar
COX-dependent mechanisms involved in the antinociceptive action of NSAIDs at central and peripheral sites

https://doi.org/10.1016/j.pharmthera.2005.02.004Get rights and content

Abstract

Despite the diverse chemical structure of aspirin-like drugs, the antinociceptive effect of NSAIDs is mainly due to their common property of inhibiting cyclooxygenases involved in the formation of prostaglandins. Prostaglandins are potent hyperalgesic mediators which modulate multiple sites along the nociceptive pathway and enhance both transduction (peripheral sensitizing effect) and transmission (central sensitizing effect) of nociceptive information. Inhibition of the formation of prostaglandins at peripheral and central sites by NSAIDs thus leads to the normalisation of the increased pain threshold associated with inflammation. The contribution of peripheral and central mechanisms to the overall antinociceptive action of NSAIDs depends on several factors including the location of the targets of drug action, the site of drug delivery and the uptake and distribution to the site of action.

The present work reviews the data on the regulation and location of cyclooxygenases at central and peripheral sites of the nociceptive pathway and focuses on the role of COX in the generation and maintenance of pain hypersensitivity. Experimental and clinical evidences are used to evaluate the significance of the peripheral and central antihyperalgesic effects of NSAIDs.

Introduction

Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most widely prescribed and widely used drugs in the management of pain, especially pain associated with inflammatory conditions. Despite the wide use of NSAIDs during the last century (the first NSAID, aspirin, was developed in the late 1800s), for a long period only little was known about the mode of action of these drugs. It was not until the 1970s that investigations into the mode of action of aspirin-like drugs were taken over by prostaglandin researchers, who showed an association between prostaglandin production and the action of aspirin-like drugs (Vane, 1964). In 1971, Vane discovered that NSAIDs could inhibit prostaglandin synthesis and proposed that this mechanism was the basis of their pharmacological action (Vane, 1971). This hypothesis was supported by other experimental data demonstrating the presence of prostaglandins at sites of inflammation (Willis, 1969, Di Rosa et al., 1971) and their ability to reproduce some of the cardinal signs of inflammation (Arora et al., 1970). The biomolecular target of NSAIDs was not identified until 1976 when a purified and enzymatically active cyclooxygenase (COX) was isolated from sheep vesicular glands (Hemler & Lands, 1976). It took several years more i.e. until the late 1980s before it was discovered that COX exists in at least two isoforms (Kujubu et al., 1991, Hla & Neilson, 1992), COX-1 and COX-2, and that “classical” NSAIDs are non-selective inhibitors of both isozymes (Xie et al., 1992).

Initially, the principle mode of the antinociceptive action of NSAIDs was considered to be related to their anti-inflammatory action and was thought to be due solely to the inhibition of prostaglandin production at the site of inflammation. This argument has its origin in the experimental observations of Horton (1963), Willis (1969), Juhlin and Michaelsson (1969), Crunkhorn and Willis (1971), Karim (1971) and, particularly, those of Ferreira (1972). By estimating pain in healthy volunteers following the intradermal administration of various inflammatory mediators (histamine, bradykinin and alprosadil (PGE1)), Ferreira could show that whilst PGE2 ‘per se’ produced no pain, its presence was essential for the induction of pain by histamine and bradykinin. These findings form the basis of the currently accepted view that PGs are not generally algogenic but act as sensitizing agents for enhancing the nociceptive properties of various inflammatory mediators. Additional evidence for the concept that NSAIDs exert their anti-nociceptive action peripherally comes from tissue distribution data obtained from whole-body autoradiography after administration of various NSAIDs in rats (Brune, 1974). In particular, it was shown that NSAIDs, because of the acidic moiety, can be extensively accumulated in inflamed tissues, where they exert their pharmacological action. At that time, the distribution of NSAIDs in other tissues, in particular in the CNS, was construed only as an explanation for the organ specific toxicity and was not thought to be related to their antinociceptive action (Brune, 1974).

The traditional belief that NSAIDs have exclusively a peripheral mode of action was not challenged until the beginning of the 1990s in the wake of the growing evidence that the anti-inflammatory and the antinociceptive effects of NSAIDs are unrelated (McCormack & Brune, 1991). So, an existence of some central antinociceptive mechanisms, an idea initially put forward by Hazlick as early as 1926 (Jurna, 1997), has been suggested (Ferreira et al., 1978, Carlsson et al., 1988). Although various mechanisms have been proposed to account for central effects of NSAIDs (Bjorkman, 1995), inhibition of prostaglandin synthesis (Abdel-Halim et al., 1978, Ferreira et al., 1978) in the CNS, and particularly in the spinal cord (Jurna et al., 1992, Malmberg & Yaksh, 1992), appears to be a property of all NSAIDs. Furthermore, the finding that both COX isozymes, i.e. COX-1 and COX-2, are expressed in the CNS (Kaufmann et al., 1997) and the observation that experimental induction of peripheral inflammation is associated with an increase in the expression of COX-2 in the spinal cord (Beiche et al., 1996) have been used as evidence supporting a central antinociceptive mechanism of action of NSAIDs (Vasquez et al., 2001, Vanegas, 2002).

This review of the central and peripheral antinociceptive mechanisms of action of NSAIDs mainly focuses on the inhibition of cyclooxygenase-mediated prostaglandin synthesis, as a class-like pharmacological property of NSAIDs. Cyclooxygenase-independent actions of NSAIDs, including cellular mechanisms mediated via interference with transcription factors (Tegeder et al., 2001b) and direct modulation of the activities of various ion channels (Lee et al., 2003), have so far only been observed with a few NSAIDs and are therefore not discussed here in detail.

The mechanisms and clinical manifestations involved in inflammatory pain, a condition commonly treated with NSAIDs, are dealt with first and this is followed by a discussion on the location and regulation of the main target of NSAIDs, cyclooxygenases at the central and peripheral sites. Biochemical aspects of prostaglandin synthesis are presented and special attention is given to the mechanisms of the prostaglandin-mediated hyperalgesia. The final section deals with the antihyperalgesic action of NSAIDs where attention is given to the currently available experimental and clinical evidence supporting their peripheral and central mechanisms. The contribution of both mechanisms to the overall antinociceptive action of this class of analgesics is discussed.

Section snippets

Inflammatory pain

The nociceptive signalling in physiological pain is initiated by activation of the specialized pain receptors (nociceptors), which are polymodal sensory fibres of the primary sensory neurons located in trigeminal and dorsal root ganglia (DRG). Although the nociceptors are able to respond to a wide range of stimulus modalities, different noxious stimuli generally cause activation of a single receptor [e.g. heat activates TRPV1-receptors (Caterina et al., 1999) and mechanical force, P2X3

Prostaglandin synthesis

Despite the diverse chemical structure of aspirin-like drugs, the antinociceptive effect of NSAIDs is mainly due to their common property of inhibiting cyclooxygenases involved in the formation of prostanoids. Prostanoids are formed by most cells and act as autocrine and paracrine lipid mediators. They are not stored but are synthesized de novo from membrane-released arachidonic acid mobilized by phospholipases (PLA2) when cells are activated by mechanical trauma, cytokines and growth factors,

Central and peripheral antihyperalgesic effects of non-steriodal anti-inflammatory drugs (NSAIDs)

NSAIDs are a disparate group of weakly acidic, highly protein-bound compounds having the common pharmacological property of inhibiting prostaglandin biosynthesis (Smith et al., 1994, Kirtikara et al., 2001). This inhibition results from a variety of effects on cyclooxygenases including the irreversible inactivation of COX (e.g. by aspirin) and reversible competitive inhibition of COX (e.g. with ibuprofen). NSAIDs usually normalise the increased pain threshold associated with inflammation rather

Conclusion

NSAIDs are potent antinociceptive agents, whose efficacy in reducing pain is widely recognized in various pain conditions, including post-surgical pain and chronic pain associated with arthritis and cancer. Although NSAIDs have long been used in clinical practice, opinion on the mechanism of their antihyperalgesic action remains controversial. According to published findings, it appears that the inhibition of prostaglandin synthesis by NSAIDs takes place at the site of peripheral inflammation

Acknowledgment

The work of the authors is supported by the Deutsche Forschungsgemeinschaft (DFG 695/2-1) and the BMBF 01EM0103.

The authors are grateful to Dr. B.G. Woodcock for the valuable editorial assistance with the manuscript.

References (166)

  • D.M. Dirig et al.

    Effect of spinal cyclooxygenase inhibitors in rat using the formalin test and in vitro prostaglandin E2 release

    Eur J Pharmacol

    (1997)
  • A. Ebersberger et al.

    The intraspinal release of prostaglandin E2 in a model of acute arthritis is accompanied by an up-regulation of cyclo-oxygenase-2 in the spinal cord

    Neuroscience

    (1999)
  • S. Ferracuti et al.

    Analgesic–antiinflammatory drugs inhibit orbicularis oculi reflexes in humans via a central model of action

    Prog Neuro-Psychopharmacol Biol Psychiatry

    (1994)
  • S.H. Ferreira et al.

    Prostaglandin hyperalgesia: IV. A metabolic process

    Prostaglandins

    (1981)
  • S.H. Ferreira et al.

    Central and peripheral antialgesic action of aspirin-like drugs

    Eur J Pharmacol

    (1978)
  • C. Forster et al.

    Measurement of the analgesic effects of aspirin with a new experimental algesimetric procedure

    Pain

    (1988)
  • R.M. Garavito et al.

    The cyclooxygenase isoforms: structural insights into the conversion of arachidonic acid to prostaglandins

    Biochim Biophys Acta

    (1999)
  • G. Geisslinger et al.

    Antinociceptive actions of R(−)-flurbiprofen—a non-cyclooxygenase inhibiting 2-arylpropionic acid—in rats

    Life Sci

    (1994)
  • M.S. Gold et al.

    Role of a Ca2+-dependent slow after hyperpolarization in prostaglandin E2-induced sensitization of cultured rat sensory neurons

    Neurosci Lett

    (1996)
  • K. Hargreaves et al.

    A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia

    Pain

    (1988)
  • C.J. Hawkey

    COX-2 inhibitors

    Lancet

    (1999)
  • C.H. Hay et al.

    Dexamethasone prevents the induction of COX-2 mRNA and prostaglandins in the lumbar spinal cord following intraplantar FCA in parallel with inhibition of oedema

    Neuropharmacology

    (1998)
  • M. Hemler et al.

    Purification of the cyclooxygenase that forms prostaglandins: demonstration of two forms of iron in the holoenzyme

    J Biol Chem

    (1976)
  • C.M. Hingtgen et al.

    Prostacyclin enhances the evoked-release of substance P and calcitonin gene-related peptide from rat sensory neurons

    Brain Res

    (1994)
  • X.Y. Hua et al.

    Inhibition of spinal protein kinase C reduces nerve injury-induced tactile allodynia in neuropathic rats

    Neurosci Lett

    (1999)
  • S. Hunskaar et al.

    The formalin test in mice: dissociation between inflammatory and non-inflammatory pain

    Pain

    (1987)
  • I. Jurna et al.

    Intrathecal injection of acetylsalicylic acid, salicylic acid and indomethacin depresses C fibre-evoked activity in the rat thalamus and spinal cord

    Pain

    (1992)
  • W.E. Kaufmann et al.

    Cyclooxygenases and the central nervous system

    Prostaglandins

    (1997)
  • T. Kawamura et al.

    Expression of prostaglandin EP2 receptor mRNA in the rat spinal cord

    Life Sci

    (1997)
  • S. Kilo et al.

    Inflammatory models of cutaneous hyperalgesia are sensitive to effects of ibuprofen in man

    Pain

    (1995)
  • D.A. Kujubu et al.

    TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue

    J Biol Chem

    (1991)
  • R. Langenbach et al.

    Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration

    Cell

    (1995)
  • H.M. Lee et al.

    Diclofenac inhibition of sodium currents in rat dorsal root ganglion neurons

    Brain Res

    (2003)
  • C. Maihofner et al.

    Localization and regulation of cyclo-oxygenase-1 and -2 and neuronal nitric oxide synthase in mouse spinal cord

    Neuroscience

    (2000)
  • A.B. Malmberg et al.

    Antinociception produced by spinal delivery of the S and R enantiomers of flurbiprofen in the formalin test

    Eur J Pharmacol

    (1994)
  • M. Matoga et al.

    Influence of a polymeric formulation of ketoprofen on its diffusion into cerebrospinal fluid in rats

    J Pharm Biomed Anal

    (2002)
  • S.T. Meller et al.

    Intraplantar zymosan as a reliable, quantifiable model of thermal and mechanical hyperalgesia in the rat

    Eur J Pain

    (1997)
  • M.S. Abdel-Halim et al.

    Inhibition of prostaglandin synthesis in rat brain

    Acta Pharm Toxicol (Copenh)

    (1978)
  • S. Ahmadi et al.

    PGE2 selectively blocks inhibitory glycinergic neurotransmission onto rat superficial dorsal horn neurons

    Nature

    (2002)
  • A.N. Akopian et al.

    A tetrodotoxin-resistant voltage-gated sodium channel expressed by sensory neurons

    Nature

    (1996)
  • I. Appleton et al.

    Distribution of cyclooxygenase isoforms in murine chronic granulomatous inflammation: implications for future anti-inflammatory therapy

    J Pathol

    (1995)
  • S. Arora et al.

    The role of prostaglandin E1 in inflammatory process in the rat

    Int Arch Allergy Appl Immunol

    (1970)
  • H. Baba et al.

    Direct activation of rat spinal dorsal horn neurons by prostaglandin E2

    J Neurosci

    (2001)
  • L.R. Ballou et al.

    Nociception in cyclooxygenase isozyme-deficient mice

    Proc Natl Acad Sci U S A

    (2000)
  • B. Bannwarth et al.

    Plasma and cerebrospinal fluid concentrations of indomethacin in humans: relationship to analgesic activity

    Eur J Clin Pharmacol

    (1990)
  • B. Bannwarth et al.

    Stereoselective disposition of ibuprofen enantiomers in human cerebrospinal fluid

    Br J Clin Pharmacol

    (1995)
  • B. Bannwart et al.

    Piroxicam concentrations in plasma and synovial fluid after a single dose of piroxicam-beta-cyclodextrin

    Int J Clin Pharmacol Ther

    (2001)
  • F. Beiche et al.

    Expression of cyclooxygenase isoforms in the rat spinal cord and their regulation during adjuvant-induced arthritis

    Inflamm Res

    (1998)
  • R. Bjorkman

    Central antinociceptive effects of non-steroidal anti-inflammatory drugs and paracetamol: experimental studies in the rat

    Acta Anaesthesiol Scand Suppl

    (1995)
  • K. Brune

    Biodistribution of salicylates: a clue to the understanding of some effects and side effects

    Agents Actions Suppl

    (1974)
  • Cited by (217)

    View all citing articles on Scopus
    View full text